PLSH

PANACEA LIFE SCIENCES HOLDINGS, INC.

OTC· Medicinal Chemicals & Botanical Products· Inc. NV· CIK 0001552189 Biotech & Drug Discovery

$0.0798 +0.00 (+0.00%)

Oct 26 4:00 PM ET · prev $0.0798

Next earnings

Nov 10

in 14 days

1 year

+14.0%

from $0.0700 · Oct 27

30 days

−0.2%

from $0.0800

52-week range

$0.0250–0.1400

−43% from high · low Apr 16

Avg volume 20D

2.1K

Oct 1 spike 12.5K

Short interest

8.4K

−0.1%

Days to cover

4.2

at average volume

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

X Jul 15 Short interest falls 98.4% to 91
X Aug 31 Short interest jumps 30.0% to 8.5K

Signal stack

Where each data set points today.

Short sellersSTEADY

Short interest −0.1% to 8.4K shares. 4.2 days to cover.
TrendDOWNTREND

6% below its 50-day average.

Recent activity

The latest filings, insider trades, analyst actions, press and options flow — newest first.

Oct 15, 2026 Event

Tacrolimus

WARNING: MALIGNANCIES AND SERIOUS INFECTIONS Increased risk for developing serious infections and ma

Aug 3, 2026 Earnings calendar

PLSH Q2 2026 Earnings Scheduled — 2026-08-03

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Upcoming

Nov 10, 2026

Earnings date

PLSH Q3 2026 Earnings Scheduled — 2026-11-10

Recent

Oct 15, 2026

FDA

Tacrolimus

WARNING: MALIGNANCIES AND SERIOUS INFECTIONS Increased risk for developing serious infections and malignancies with tacrolimus or other immunosuppress

Aug 3, 2026

Earnings date

PLSH Q2 2026 Earnings Scheduled — 2026-08-03

May 12, 2026

Earnings date

PLSH Q1 2026 Earnings Scheduled — 2026-05-12

Mar 30, 2026

Earnings date

PLSH Q4 2025 Earnings Scheduled — 2026-03-30

May 27, 2015

Clinical Trial

a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients

Phase 3 · COMPLETED

Earnings setup

Estimates

Nov 10

reports in 14 days

Period	EPS est.	Range	30D rev.	Revenue
Current Q	—	—	—	$0.00
Next Q	—	—	—	$0.00
Current FY	—	—	—	$0.00
Next FY	—	—	—	$0.00

Short side

FINRA· Sep 15, 2026

8,446

shares short

-0.1%

vs prior settlement

4.2

days to cover